93 related articles for article (PubMed ID: 26003885)
1. A plant cell model of polyglutamine aggregation: Identification and characterisation of macromolecular and small-molecule anti-protein aggregation activity in vivo.
Liu G; Hu Y; Tunnacliffe A; Zheng Y
J Biotechnol; 2015 Aug; 207():39-46. PubMed ID: 26003885
[TBL] [Abstract][Full Text] [Related]
2. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models.
Ehrnhoefer DE; Duennwald M; Markovic P; Wacker JL; Engemann S; Roark M; Legleiter J; Marsh JL; Thompson LM; Lindquist S; Muchowski PJ; Wanker EE
Hum Mol Genet; 2006 Sep; 15(18):2743-51. PubMed ID: 16893904
[TBL] [Abstract][Full Text] [Related]
3. Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions.
Davranche A; Aviolat H; Zeder-Lutz G; Busso D; Altschuh D; Trottier Y; Klein FA
Hum Mol Genet; 2011 Jul; 20(14):2795-806. PubMed ID: 21518730
[TBL] [Abstract][Full Text] [Related]
4. Modulating huntingtin half-life alters polyglutamine-dependent aggregate formation and cell toxicity.
Kaytor MD; Wilkinson KD; Warren ST
J Neurochem; 2004 May; 89(4):962-73. PubMed ID: 15140195
[TBL] [Abstract][Full Text] [Related]
5. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin.
Wang H; Lim PJ; Yin C; Rieckher M; Vogel BE; Monteiro MJ
Hum Mol Genet; 2006 Mar; 15(6):1025-41. PubMed ID: 16461334
[TBL] [Abstract][Full Text] [Related]
6. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
[TBL] [Abstract][Full Text] [Related]
7. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity.
Khoshnan A; Ko J; Patterson PH
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):1002-7. PubMed ID: 11792860
[TBL] [Abstract][Full Text] [Related]
8. Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease.
Skogen M; Roth J; Yerkes S; Parekh-Olmedo H; Kmiec E
BMC Neurosci; 2006 Oct; 7():65. PubMed ID: 17014717
[TBL] [Abstract][Full Text] [Related]
9. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.
Lecerf JM; Shirley TL; Zhu Q; Kazantsev A; Amersdorfer P; Housman DE; Messer A; Huston JS
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4764-9. PubMed ID: 11296304
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of the first 17 amino acids of huntingtin in Huntington's disease.
Arndt JR; Chaibva M; Legleiter J
Biomol Concepts; 2015 Mar; 6(1):33-46. PubMed ID: 25741791
[TBL] [Abstract][Full Text] [Related]
11. Genetic ablation and chemical inhibition of IP3R1 reduce mutant huntingtin aggregation.
Bauer PO; Hudec R; Ozaki S; Okuno M; Ebisui E; Mikoshiba K; Nukina N
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):13-7. PubMed ID: 22056561
[TBL] [Abstract][Full Text] [Related]
12. Huntingtin with an expanded polyglutamine repeat affects the Jab1-p27(Kip1) pathway.
Cong SY; Pepers BA; Zhou TT; Kerkdijk H; Roos RA; van Ommen GJ; Dorsman JC
Neurobiol Dis; 2012 Jun; 46(3):673-81. PubMed ID: 22426400
[TBL] [Abstract][Full Text] [Related]
13. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation.
Wang J; Gines S; MacDonald ME; Gusella JF
BMC Neurosci; 2005 Jan; 6():1. PubMed ID: 15649316
[TBL] [Abstract][Full Text] [Related]
14. Antisense downregulation of mutant huntingtin in a cell model.
Hasholt L; Abell K; Nørremølle A; Nellemann C; Fenger K; Sørensen SA
J Gene Med; 2003 Jun; 5(6):528-38. PubMed ID: 12797118
[TBL] [Abstract][Full Text] [Related]
15. Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates.
Fukui H; Moraes CT
Hum Mol Genet; 2007 Apr; 16(7):783-97. PubMed ID: 17356014
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a recruitment and sequestration mechanism in Huntington's disease.
Preisinger E; Jordan BM; Kazantsev A; Housman D
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1029-34. PubMed ID: 10434302
[TBL] [Abstract][Full Text] [Related]
17. Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract.
Hazeki N; Nakamura K; Goto J; Kanazawa I
Biochem Biophys Res Commun; 1999 Mar; 256(2):361-6. PubMed ID: 10079189
[TBL] [Abstract][Full Text] [Related]
18. Both plant and animal LEA proteins act as kinetic stabilisers of polyglutamine-dependent protein aggregation.
Liu Y; Chakrabortee S; Li R; Zheng Y; Tunnacliffe A
FEBS Lett; 2011 Feb; 585(4):630-4. PubMed ID: 21251910
[TBL] [Abstract][Full Text] [Related]
19. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease.
Lee WC; Yoshihara M; Littleton JT
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3224-9. PubMed ID: 14978262
[TBL] [Abstract][Full Text] [Related]
20. Aggregation in Huntington's disease: insights through modelling.
Cajavec B; Bernard S; Herzel H
Genome Inform; 2005; 16(1):262-71. PubMed ID: 16362929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
